

Curriculum Vitae
Richard W. Lowry, Jr, MD, FACC, FSCAI

Address: 1783 Troup Hwy
Tyler, Texas 75701

Telephone: Office (903)-595-2283
Fax (903)-597-2238

Date of Birth: October 2, 1961
Tulsa, Oklahoma

Practice

2009-Present Tyler Cardiac and Endovascular Center
1769 Troup Hwy, Tyler, Texas

2006-Present Cardiovascular Associates of East Texas, P.A., Tyler, Texas

1994-2006 Cardiology of Tulsa, Tulsa, Oklahoma

Affiliation

2006-Present CAET - Research
1761 Troup Hwy, Tyler, Texas

1/1/13-4/26/13 TAD Clinical Research
1741 Troup Hwy, Tyler, Texas

Education

1983-1987 University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.
Doctor of Medicine, 1987

1979-1983 Stanford University, Palo Alto, California
Bachelor of Arts in Human Biology, 1983

Post-Graduate Training

7/1993-6/1994 Fellowship in Interventional Cardiology, Baylor College of Medicine
Affiliated Hospitals, Houston, Texas

1991-1992 Fellowship in Heart Failure and Cardiac Transplant, Baylor College of
Medicine Affiliated Hospitals, Houston, Texas

7/1990-6/1994 Fellowship in Cardiology, Baylor College of Medicine Affiliated Hospitals,
Houston, Texas

7/1987-6/1990 Residency in Medicine, Charity Hospital
Veterans Administration Hospital and Tulane Medical Center
New Orleans, Louisiana

7/1987-6/1988 Internship in Medicine, Charity Hospital
Veterans Administration Hospital and Tulane Medical Center
New Orleans, Louisiana

Board Certification

2014 American Board of Internal Medicine
Subspecialty Board of Heart Failure/Transplantation

1999, 2009 American Board of Internal Medicine,
Subspecialty Board of Interventional Cardiology #134899

2006 International Board of Heart Rhythm Examiners, Formerly NASPE Exam #1172

1993, 2003 American Board of Internal Medicine
Subspecialty Board of Cardiovascular Disease #134899

Licensure

1990, 2006 State of Texas #H8733

1994 State of Oklahoma #19408(7/01/1994)

1987 State of Louisiana #07638R

Hospital Appointments

Trinity Mother Frances Hospital, Tyler, Texas

East Texas Medical Center, Tyler, Texas

East Texas Medical Center, Athens, Texas

East Texas Medical Center, Carthage, Texas

East Texas Medical Center, Quitman, Texas

Nacogdoches Memorial Hospital, Nacogdoches, Texas

Texas Spine and Joint Hospital, Tyler, Texas

Memberships

2001 Fellow of The Society for Cardiac Angiography and Interventions (FSCAI)

1995 Fellow of American College of Cardiology (FACC)

1987 American Medical Association

Professional Activities

- 1999-Present Editorial Consultant
The Society for Cardiac Angiography and Interventions
- 1997-Present Medical Advisory Board
Scimed

Research

Co-Investigator – CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (Iorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

Co-Investigator – AVERT - “A prospective, randomized, parallel group, multi-center clinical evaluation, to assess the AVERT system device for CM volume reduction and incidence of CIN”.

Co-Investigator – LIBERTY 360 - Prospective, observational, multi-center clinical study to evaluate endovascular device interventions in treating lower extremity PAD with critical limb ischemia (CLI) and/or intermittent claudication.

Co-Investigator – MIMICS-2 - Evaluation of Safety and Efficacy of the BioMimics 3DTM Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease

Co-Investigator – ANALYZE ST - Monitoring to Detect ACS Events in ICD Patients (Analyze ST)

Co-Investigator – ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Co-Investigator – SUMMIT - HZC113782 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

Co-Investigator – DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator – ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Co-Investigator – AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator – EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator – EUCLID -A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator – PARADIGM - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Co-Investigator – TRACER – " A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome."

Co-Investigator – Quick FLEX Model 1258T Left Heart Pacing Lead Post Approval Study.

Co-Investigator – VISTA – 16 – Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes.

Co-Investigator – TAO – Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial Infarction scheduled to undergo an early invasive strategy.

Co-Investigator – LIBERTE – "A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Liberte-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen.

Co-Investigator – RESOLUTE US – A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of *De Novo* Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm.

Co-Investigator – ENDEAVOR SVS – A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of *De novo* Lesions in Small Diameter Native Coronary Arteries.

Co-Investigator – The Complete® SE SFA Study: The Medtronic Complete Self-Expanding(SE) SFA Stent for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery

Co-Investigator - OPTIMUM Registry - A prospective, outcome-oriented registry of patients implanted with SJM Optim™ leads. This registry evaluated the chronic performance of the market-released SJM Cardiac Rhythm Management (CRM) leads with Optim™ insulation material.

Co-Investigator - RATE Registry – Registry of AT/AF Episodes in the CRM Device Population.

Primary Investigator - PLATO Study - A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS).

Co Investigator – LEAP -- A Two Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Simvastatin, Losartan, and Pioglitazone on Cardiovascular disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Artery Disease.

Co-Investigator – RE-LY - **R**andomized **E**valuation of **L**ong term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.

Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

BEST – Beta-blocker evaluation of survival trial. Mortality study to evaluate Bucindolol versus placebo in patients with Class III/IV CHF and EF < 35%. (NHLBI & VA Cooperative Studies Program)

PRAISE-2 - Prospective Randomized Amlodipine Survival Evaluation-2. To evaluate the effect of amlodipine on survival in patients with congestive heart failure (non-ischemic etiology) and EF < 30%. No beta blocker allowed. (Pfizer, Inc.)

Val-Heft - Valsartan in heart failure. Placebo controlled study to evaluate the effect of Valsartan on morbidity and mortality, signs and symptoms and quality of life in patients with stable, chronic CHF (NYHA Class II-IV). EF < 40%. May be on beta blocker. (Novartis)

SCD-HeFT – Sudden cardiac death in heart failure trial. Amiodarone vs. an implantable cardioverter – defibrillator (ICD) vs. placebo (I:I) in the treatment of patients with NYHA II/III CHF. EF < 35%. (NHLBI)

RENAISSANCE – Multi-center, double-blind, randomized, placebo-controlled, Phase II/III study of the effect of recombinant human tumor necrosis factor receptor Fe fusion protein (TNFR:Fe)(etanercept) on clinical improvement in patients with chronic heart failure.

SPORT – Stent implantation post rotational atherectomy trial.

Wallstent Study – WIN – Wallstent in native coronary arteries. Nonrandomized – all patients who qualify get Wallstent. WINS – Wallstent in SV-CABG vessels. Randomized to Wallstent or J&J stent (1:1). (Schneider)

In Time-II – Double-blind, randomized, multicenter trial of single-bolus Lanoteplase versus accelerated alteplase for the treatment of subjects with acute myocardial infarction. Randomized 2:1, chest pain x 30 minutes within 6 hours. (Bristol-Myers Squibb).

SADHART – A randomized double-blind, placebo-controlled trial of sertraline (Zoloft) for major depression after myocardial infarction. MI within 30 days. (Pfizer and Duke).

GEM DR – Evaluation of patients implanted with an implantable cardioverter defibrillator combined with a dual chamber rate responsive pacemaker. Inclusion criteria: one episode of sudden cardiac death or recurrent poorly tolerated sustained VT. (Medtronic)